diate obligations to make essential drugs universally available now, and (2) progressive obligations to improve access to a broadened definition of needed medicines over time;iii. promoting meaningful participation by affected individuals and groups in decisions that affect access to medicines, including drug regulatory and pricing decisions and decisions to grant or revoke patents on pharmaceutic